Core Laboratories posts Q4 2025 results and dividend

Core Laboratories ( (CLB) ) has shared an announcement.

On February 4, 2026, Core Lab reported fourth-quarter 2025 revenue of $138.3 million, up 7% year over year, operating income of $15.8 million, GAAP EPS of $0.15, and free cash flow of $5.1 million while trimming net debt and repurchasing 363,207 shares; full-year revenue reached $526.5 million with $26 million in free cash flow and $18.7 million of net-debt reduction. The company declared a $0.01-per-share quarterly dividend payable March 9, 2026, underscoring its capital-return strategy as international demand for reservoir studies and adoption of proprietary PAC and SpectraStim technologies bolstered its asset-light model despite softer U.S. land activity and margin pressure.

The most recent analyst rating on (CLB) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Core Laboratories stock, see the CLB Stock Forecast page.

Spark’s Take on CLB Stock

According to Spark, TipRanks’ AI Analyst, CLB is a Outperform.

Core Laboratories is on a positive trajectory with strong financial health and technical momentum. The company’s strategic initiatives and solid cash flow conversion are significant strengths. However, valuation concerns and external challenges like geopolitical tensions pose risks. Overall, the stock presents a balanced opportunity with potential for growth.

To see Spark’s full report on CLB stock, click here.

More about Core Laboratories

Core Laboratories Inc. is a Houston-based oilfield services firm specializing in reservoir description and production enhancement technologies, supplying international and offshore operators with proprietary laboratory analytics and completion tools.

Average Trading Volume: 383,315

Technical Sentiment Signal: Hold

Current Market Cap: $912.2M

Find detailed analytics on CLB stock on TipRanks’ Stock Analysis page.